+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2020 UK Cancer Diagnostics Market: Supplier Shares by Test, Competitive Strategies, Volume and Sales Segment Forecasts, Emerging Technologies, Latest Instrumentation

  • ID: 4911998
  • Report
  • January 2020
  • Region: United Kingdom
  • 565 pages
  • VPG Market Research
1 of 2

FEATURED COMPANIES

  • Abbott
  • Bio-Rad
  • Eiken Chemical
  • Hologic
  • PerkinElmer
  • Siemens Healthineers
  • MORE

This new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the UK cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

  • Specific new product development opportunities with potentially significant market appeal during the next five years.
  • Design criteria for new products.
  • Alternative market penetration strategies.
  • Potential market entry barriers and risks.

Cancer Diagnostic Tests & Over 200 current and emerging assays including:
ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

  • Sales and market shares of major suppliers, by individual cancer diagnostic test.
  • Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:
  • Hospitals
  • Commercial/Private Laboratories
  • Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.
  • Cancer statistics, etiology and recent developments.

Current and Emerging Products

  • Review of over 200 current and emerging cancer diagnostic tests, including:
  • Biochemical Markers
  • Oncogenes
  • Growth Factors
  • Hormones
  • Colony Stimulating Factors
  • Lymphokines
  • Immunohistochemical Stains, and others.
  • Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

  • Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
  • Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
  • Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

  • Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
Note: Product cover images may vary from those shown
2 of 2

Loading
LOADING...

3 of 2
  • Abbott
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • bioMerieux
  • Bio-Rad
  • CellSearch
  • Cepheid
  • Clinical Genomics
  • Decode Genetics
  • DiaSorin
  • Diazyme
  • Eiken Chemical
  • Elitech Group
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Guided Therapeutics
  • Hologic
  • Janssen Diagnostics
  • Kyowa Medex
  • Leica Biosystems
  • Myriad Genetics
  • OncoLab
  • Ortho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • PerkinElmer
  • Polymedco
  • Qiagen
  • Quest Diagnostics
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthineers
  • Takara Bio
  • Theradiag
  • Thermo Fisher
  • Tosoh
  • Vermillion
  • Wako Pure Chemicals
Note: Product cover images may vary from those shown
Adroll
adroll